Enhancing solubility of targeted protein degraders: Better strategies for bioavailability
Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to administer medication while also enabling these drugs to penetrate the blood-brain barrier, crucial for treating neurodegenerative diseases effectively. Expert Rebbeca Coutts explains how addressing these challenges has influenced TPD development and is driving innovation in formulation technologies.
